Developing and interpreting highly sensitive GLP and non-GLP assays to identify potential carcinogenic, mutagenic and toxic risks requires experience, expertise and the ability to understand that every project is different. Whether you are in the pharmaceutical, biopharmaceutical, chemical, crop protection, food additive or animal health industry, we’re ready to work closely with you to deliver regulatory-compliant reports.

We are the developers of a number of non-GLP screening studies, allowing you to get results in a few days using less sample article, including our microAmes Screen, the first mutagenicity screen that predicts the GLP regulatory Ames Test. Our micro-clastogenicity screen is ideal for predicting the Regulatory Chromosome Aberration Test.

We’re ready to talk about your needs.

 
Sample GLP and non-GLP capabilities

• In vitro studies
• In vitro screening studies
• in vivo studies
• in vivo screening studies
• Standard ICH core battery tests
• Genotoxic impurity testing
• ADME
• Absorption studies
• Metabolism: Cytochrome P450 identification/inhibition/induction, metabolite profiling